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Abstract
Background: Folate and vitamin B12 are essential for maintaining DNA integrity and
may influence prostate cancer (PCa) risk, but the association with clinically relevant,
advanced stage, and high-grade disease is unclear.
Objective: To investigate the associations between circulating folate and vitamin B12
concentrations and risk of PCa overall and by disease stage and grade.
Design, setting, and participants: A study was performed with a nested case–control
design based on individual participant data from six cohort studies including 6875 cases
and 8104 controls; blood collection from 1981 to 2008, and an average follow-up of
8.9 yr (standard deviation 7.3). Odds ratios (ORs) of incident PCa by study-speciﬁc ﬁfths
of circulating folate and vitamin B12 were calculated using multivariable adjusted
conditional logistic regression.
Outcomemeasurements and statistical analysis: Incident PCa and subtype by stage and
grade.
Results and limitations: Higher folate and vitamin B12 concentrations were associated
with a small increase in risk of PCa (ORs for the top vs bottom ﬁfths were 1.13 [95%
conﬁdence interval (CI), 1.02–1.26], ptrend = 0.018, for folate and 1.12 [95% CI, 1.01–1.25],
ptrend = 0.017, for vitamin B12), with no evidence of heterogeneity between studies. The
association with folate varied by tumour grade (pheterogeneity< 0.001); higher folate
concentration was associated with an elevated risk of high-grade disease (OR for the
top vs bottom ﬁfth: 2.30 [95% CI, 1.28–4.12]; ptrend = 0.001), with no association for low-
gradedisease. Therewasno evidence of heterogeneity in the association of folatewith risk
by stageor of vitaminB12with risk by stage or gradeof disease (pheterogeneity> 0.05). Use of
single blood-sample measurements of folate and B12 concentrations is a limitation.
Conclusions: The association between higher folate concentration and risk of high-
grade disease, not evident for low-grade disease, suggests a possible role for folate in the
progression of clinically relevant PCa and warrants further investigation.
Patient summary: Folate, a vitamin obtained from foods and supplements, is important
for maintaining cell health. In this study, however, men with higher blood folate levels
were at greater risk of high-grade (more aggressive) prostate cancer comparedwithmen
with lower folate levels. Further research is needed to investigate the possible role of
folate in the progression of this disease.
# 2016 European Association of Urology. Published by Elsevier B.V. This is an open
access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Folate and vitamin B12 are essential for maintaining healthy
patterns of DNA methylation, repair, and synthesis [1], and
low availability of these vitamins may influence cancer
development through altered methylation patterns
[2]. However, a meta-analysis of prospective studies
published up to 2009 reported that higher concentrations
of folate and vitamin B12 were associated with a modest
increase in prostate cancer (PCa) risk [3]. Interpretation of
these findings is challenging because of the heterogeneous
nature of PCa, with many tumours remaining small and
asymptomatic for long durations of time [4], whereas some
develop into aggressive forms and are ultimately lethal
[5,6]. The use of prostate-specific antigen (PSA) testing has
led to much earlier detection of localised cancers, many of
which may never progress to aggressive disease [7]. There-
fore, the identification of risk factors for PCa needs to take
into account differences in stage and grade of the disease.
To investigate the association between circulating folate
and vitamin B12 concentrations and risk of PCa and, in
particular, whether these associations differ by stage and
grade of disease, individual participant data from six cohort
studies participating in the Endogenous Hormones, Nutri-
tional Biomarkers, and Prostate Cancer Collaborative Group
were assessed.2. Materials and methods
2.1. Study populations
Studies were eligible for inclusion in this individual participant
collaboration if they had data on circulating concentrations of folate
and/or vitamin B12 and subsequent PCa risk for aminimumof 75 incident
cases. Studies were identiﬁed by using the search terms folate, folic acid,
vitamin B12, and cobalamin, together with the MeSH term prostatic
neoplasms and text term PCa from review articles; literature searches
using PubMed, Web of Science, Cochrane Library, and CancerLit (up to
January 2015); and from discussions with colleagues.
Seven eligible studies were identiﬁed [3,8–12], of which six are
included in this analysis; one research group declined to participate in
this collaboration [11]. Studies provided data in predeﬁned case–control
sets matched on age at recruitment, date of blood collection (or follow-
up time), and, if appropriate, other matching criteria as speciﬁed by the
original study investigators (Supplementary Table 1). The Carotene and
Retinol Efﬁcacy Trial (CARET [13]; unpubl. data), the European
Prospective Investigation into Cancer and Nutrition study (EPIC) [9],
the Northern Sweden Health and Disease Study cohort (NSHDC) [8], and
the Janus study [12] used a matched nested case–control study design
within a prospective cohort. The remaining two studies were observa-
tional studies conductedwithin randomised controlled trials. The Alpha-
Tocopherol, Beta-Carotene Cancer Prevention Study (ATBC) [10]
provided cases and controls matched on intervention group. The
Prostate Testing for Cancer and Treatment Trial (ProtecT) [3] is a trial
of different treatments for PCa in which men underwent PSA testing at
[(Fig._1)TD$FIG]
Fig. 1 – Odds ratios and 95% confidence intervals for prostate cancer by study-specific fifths of circulating folate and vitamin B12 concentrations. The
odds ratios are conditioned on the matching variables and adjusted for exact age, marital status, education level, cigarette smoking, height, and body
mass index. The p value for trend was calculated by replacing the fifths of folate concentration with a continuous variable that was scored 0, 0.25, 0.5,
0.75, and 1 in the conditional logistic regression model.
80%le = 80 percentile; CI = confidence interval; OR = odds ratio; Ptr = p value for trend.
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data from ProtecT are reported in this study because, on average, the
blood was collected several years before the cancer would have been
diagnosed in an unscreened population [14].
Individual participant data on circulating folate were available for
6875 cases and 8104 controls, representing 97% of the existing
observational data. Data were available on circulating vitamin B12 for
6735 cases and 7959 controls, representing—to our knowledge—all
existing data.
2.2. Data processing
Details of the study design, methods of recruitment, ethics approval,
funding, and informed consent are available in the original publications
[3,8–10,12]. The Janus and ProtecT data sets were identical to those
analysed and published by the original research group. Data sets
provided by the EPIC and NSHDC studies included additional case–
control sets that were not included in the original reports; the CARET
study provided (as yet) unpublished data.
Data for individual men were requested for circulating folate and
vitamin B12 concentrations (details of the assay methods are available in
Supplementary Table 2) and a variety of other factors, including date and
time of blood collection, date of birth (or age at blood collection), fasting
status, marital status, ethnicity, educational attainment, family history
of PCa, height, weight, smoking status, alcohol intake, date of diagnosis,
and stage and grade of disease. To provide a common deﬁnition across
studies, PCa stage was deﬁned as localised if it was TNM stage T2 or lower
and N0 or NX and M0, or equivalent (ie, tumour not extending beyond
the prostate capsule and with no lymph node involvement or distant
metastases); as advanced stage if it was T3 or T4 and/or N1+ and/orM1, or
equivalent (ie, tumour extending beyond the prostate capsule with or
without lymph node involvement and/or distant metastases); or as
unknown. Aggressive disease was categorised as no for TNM stage T0, T1,
T2, or T3 with no reported lymph node involvement or metastases or
equivalent; as yes for TNM stage T4 and/or N1+ and/or M1 and/or stage
IV disease or death from PCa; or as unknown. PCa grade was deﬁned as
low-intermediate if the Gleason sum was <8 or equivalent (ie, extent of
differentiation good, moderate, or poor); as high grade if the Gleason sum
was 8 or equivalent (ie, undifferentiated); or as unknown. Summarydata were given to collaborators for ﬁnal conﬁrmation before inclusion
in the analytic data set.
2.3. Statistical analysis
To allow for possible systematic differences between studies in assay
methods, storage conditions, and blood sample types, study-speciﬁc
quintile cut points were used to categorise men into ﬁfths of circulating
folate and vitamin B12 concentration based on the distribution in control
participants. The main method of analysis was logistic regression
conditioned on the matching variables within each study. To provide a
summary measure of the odds ratio (OR), the categorical variable
representing the ﬁfths of the circulating folate and vitamin B12
concentration was replaced with a continuous variable scored 0, 0.25,
0.5, 0.75, and 1, from the lowest to the highest ﬁfth. Themidpoints of the
lowest and highest ﬁfths are the 10th and 90th percentiles of the study-
speciﬁc concentration of folate and vitamin B12, hence a unit increase
represents an 80-percentile increase in the study-speciﬁc analyte
concentration. Age at blood collection, body mass index (BMI; <25,
25–27.4, 27.5–29.9, 30 kg/m2 or unknown), height (170, 171–175,
176–180,>180 cmor unknown), marital status (married/cohabiting, not
married/cohabiting, unknown), educational status (below secondary/
high school, secondary/high school/college, university, unknown), and
cigarette smoking (never, past, current smoker, unknown) were
associated with PCa risk and were included as covariates.
Heterogeneity in linear trends for PCa risk between studies was
tested by comparing the x2 values for models with and without a study-
times-linear trend interaction term. To test whether the linear trend
estimates for each biomarker varied according to certain participant
characteristics, ORs were estimated for subgroups of the following
characteristics: age at diagnosis, years from blood collection to
diagnosis, year of diagnosis, stage of disease, aggressive disease, grade
of disease, age at blood collection, BMI, cigarette smoking, alcohol
consumption, and family history of PCa (all categories as shown in Fig. 3a
and 3b). Information on cancer stage was available for between 61% and
99% of cases across all of the studies; information on cancer grade was
available for 79% to 99% of cases, with the exception of Janus, for which
no data on grade were available. Cases and their matched controls were
excluded from the analyses if the relevant informationwas not available.
Table 1 – Participant characteristics by study and case-control status
Study Case–
control
status
Participants,
N
Age at blood
collection,
yr, mean (SD)
Date of
blood collection,
minimum-maximum
BMI, kg/m2,
mean (SD)
Higher
education,
%
Current
smokers,
%
Geometric mean (95% CI)
Folate,
nmol/l
Vitamin B12,
pmol/l
ATBC Case 224 60.9 (5.0) 1985–1988 26.4 (3.5) 3.6 100.0 8.6 (8.2–9.0) 344 (328–360)
Control 440 60.7 (4.8) 1985–1988 25.9 (3.6) 5.5 100.0 8.5 (8.2–8.8) 342 (330–355)
CARET Case 389 62.3 (5.7) 1985–1997 28.5 (4.3) 24.3 52.2 15.3 (14.3–16.5) 299 (288–311)
Control 773 62.1 (5.8) 1985–1996 28.3 (4.5) 23.0 52.1 15.5 (14.7–16.3) 307 (298–316)
EPIC Case 1244 60.0 (6.6) 1989–2003 26.8 (3.4) 25.4 20.9 13.8 (13.3–14.3) 332 (324–340)
Control 1341 59.8 (6.6) 1989–2003 26.8 (3.6) 22.6 23.3 12.7 (12.3–13.2) 327 (321–334)
Janus Case 3000 48.7 (8.8) 1981–2002 25.6 (3.0) NA 39.4 14.1 (14.0–14.3) 451 (445–458)
Control 3000 48.6 (8.7) 1981–2002 25.7 (3.1) NA 39.7 13.9 (13.8–14.1) 444 (438–450)
NSHDC Case 560 56.6 (5.2) 1986–2004 26.0 (3.1) 13.4 28.9 5.9 (5.7–6.2) 334 (326–342)
Control 1044 56.5 (5.2) 1986–2004 26.2 (3.5) 13.0 25.1 5.7 (5.5–5.9) 320 (313–328)
ProtecT Case 1458 62.0 (5.1) 2003–2008 26.7 (3.4) NA 14.3 16.5 (15.9–17.0) 301 (295–307)
Control 1506 61.8 (5.1) 2003–2008 26.9 (3.8) NA 12.5 16.9 (16.4–17.5) 295 (289–300)
ATBC = Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study; BMI = body mass index; CARET = Carotene and Retinol Efﬁcacy Trial; CI = conﬁdence
interval; EPIC = European Prospective Investigation into Cancer and Nutrition; NA = data not available; NSHDC = Northern Sweden Health and Disease Study
cohort; ProtecT = Prostate Testing for Cancer and Treatment Trial; SD = standard deviation.
The numbers of cases and controls are the maximum number for whom folate and vitamin B12 measurements were available.
E U RO P E AN URO LOGY 7 0 ( 2 0 1 6 ) 9 4 1 – 9 5 1944Tests for heterogeneity of trends for the case-deﬁned factors (ie, age
at diagnosis, year of diagnosis, stage of disease, grade of disease, time
between blood collection and diagnosis), in which controls in each
matched set were assigned the value of their matched case, were
obtained by ﬁtting separate models for each subgroup and assuming
independence of the ORs using a method analogous to a meta-analysis.
Tests for heterogeneity of trends for the non–case-deﬁned factors (eg,
age at blood collection and cigarette smoking) were assessed using a x2-
test of interaction between subgroup and the continuous trend test
variable. For advanced stage, aggressive disease, and high-grade disease,
further analyses were performed by calculating ORs in ﬁfths of the
distribution deﬁned by the study-speciﬁc quintiles of the distribution in
the controls matched with each subset of cases.
Natural logarithmic transformations of folate and vitamin B12 values
were used to approximate a normal distribution, and geometric mean
concentrations of circulating folate and vitamin B12 were calculated
according to a variety of factors in control participants, with adjustment
for study and age at blood collection, using analysis of variance.
All statistical analyses were carried out using Stata (release 12;
StataCorp, College Station, TX, USA). A p value <0.05 was considered
statistically signiﬁcant.3. Results
Data were available for up to 6875 PCa cases and
8104 controls from six studies with a mean follow-up time
of 8.9 yr (standard deviation: 7.3 yr). The mean age of
control participants at blood collection ranged from 48.6 to
62.1 yr, and mean BMI varied from 25.7 to 28.3 kg/m2
(Table 1). Between 13% and 40% of control participants were
current smokers, except in ATBC (100%), which recruited all
smokers, and CARET (52%), which recruited current and
former heavy smokers. Blood collection dates varied
between 1981 and 2008. There was substantial variation
across the studies in the time between blood collection and
PCa diagnosis: >50% of cases were diagnosed >5 yr after
blood collection in ATBC, EPIC, Janus, and NSHDC. In
contrast, all cases fromProtecT and 82% of cases fromCARETwere diagnosed within 5 yr of blood collection (Table 2). In
all studies, 66% of cases were diagnosed in men aged 60
yr, with most cases diagnosed with localised (>50%) and
low grade (>85%) disease, if known.
Geometric mean folate concentrations (among controls)
ranged from 5.7 nmol/l in NSHDC to 16.9 nmol/l in ProtecT.
Vitamin B12 concentration ranged from 295 pmol/l in
ProtecT to 444 pmol/l in Janus. Folate concentration was
higher in older age groups, in those with a higher level of
education, in never smokers, and in those who had higher
alcohol consumption (Supplementary Fig. 1a). Vitamin B12
concentration was higher in younger age groups and in
those with lower education and lower alcohol consumption
(Supplementary Fig. 1b). The correlation between log-
transformed folate and vitamin B12 concentration was of a
small magnitude although highly statistically significant
(partial correlation adjusted for age at blood collection in
five groups: r = 0.11; p < 0.0001).
Circulating concentrations of both folate and vitamin B12
were positively associated with risk of PCa; the ORs for the
top versus bottom fifths were 1.13 (95% confidence interval
[CI], 1.02–1.26) for folate and 1.12 (95% CI, 1.01–1.25) for
vitamin B12 (Fig. 1), with no evidence of heterogeneity
between the studies for both analytes (pheterogeneity > 0.05).
Owing to the cross-sectional nature of the study design,
analyses were also performed after excluding ProtecT (with
1458 cases and 1506 controls); the association of folatewith
PCa risk was slightly strengthened (Fig. 2a ) (OR per 80-
percentile increase: 1.17 [95% CI, 1.05–1.31]; p = 0.004),
whereas the association with vitamin B12 was slightly
attenuated (Fig. 2b) (OR: 1.11 [95% CI, 0.99–1.24]; p = 0.06).
The association of circulating folate concentration with
PCa risk differed by grade of disease (pheterogeneity < 0.001),
with a higher folate concentration associated with an
increased risk of high-grade disease (OR per 80% increase:
2.50 [95% CI, 1.49–4.21]) but not with low-grade disease
(OR per 80% increase: 1.01 [95% CI, 0.87–1.16]) (Fig. 3a).
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increased risk of advanced disease (OR per 80% increase:
1.35 [95% CI, 1.07–1.72]) and aggressive disease (OR per 80%
increase: 1.39 [95% CI, 1.03–1.88]), although, for these end
points, the differences between the subgroups were not
statistically significant (Fig. 3a). To examine in more detail
the association of circulating folate concentration with risk
of advanced stage, aggressive, and high-grade disease,
analyses were performed across the study-specific fifths of
folate concentration (Fig. 4a–4c). The ORs for the top versus
bottom fifths of folate were 1.31 (95% CI, 1.00–1.71;
ptrend = 0.01) for advanced stage disease, 1.30 (95% CI,
0.93–1.81; ptrend = 0.03) for aggressive disease, and 2.30
(95% CI, 1.28–4.12; ptrend = 0.001) for high-grade disease.
The association of circulating vitamin B12 with PCa risk
did not differ by stage or grade of disease (Fig. 3b)
(pheterogeneity > 0.05). There was some evidence of hetero-
geneity in the association with vitamin B12 by smoking
status, with a higher concentration of vitamin B12 associat-
ed with an increased risk of PCa in never smokers (OR per
80% increase: 1.37 [95% CI, 1.14–1.65]) but not in past or
current smokers (pheterogeneity = 0.03).We also examined the
joint effects of folate and vitamin B12 in relation to PCa and
found no evidence of interaction (pheterogeneity = 0.27)
(Supplementary Table 3).4. Discussion
The findings from this individual participant pooled
analysis of 6875 cases and 8104 controls represent almost
all of the existing observational data from cohort studies
for the association of circulating concentrations of folate
and vitamin B12 with risk of PCa. Our results provide
evidence ofweak positive associations between circulating
concentrations of both folate and vitamin B12 and risk of
PCa. Furthermore, the finding that a higher folate concen-
trationwas associated with an increased risk of high-grade
disease but not low grade-disease suggests that the
possible role of folate in PCa progression warrants further
investigation.
The effect of folic acid supplementation on cancer risk
has also been investigated. An individual participant meta-
analysis of randomised trials [15], with 656 incident PCa
cases and an average of 5.2 yr of treatment, reported a
modest (15%) but nonsignificant increased risk in the
supplement versus placebo arms (95% CI, 1% to 34%);
however, the median circulating folate concentration in the
supplement arm was substantially higher than that
observed in our study, and associations by stage or grade
of disease were not assessed [15].
The role that circulating concentrations of folate might
play in risk of high-grade disease and, to a lesser extent,
advanced stage and aggressive disease is unclear. In vitro
models using human prostate tissue have shown enhanced
proliferation of tumour cells with elevated folate concen-
trations [16], and lower cellular proliferation has been
observed in transgenic adenoma of mouse prostate
(TRAMP) mice fed a folate-depleted diet compared with
[(Fig._2)TD$FIG]
Fig. 2 – Study-specific odds ratios and 95% confidence intervals for prostate cancer per 80 percentile increase (a) in circulating folate and (b) in
circulating vitamin B12. The odds ratios are conditioned on the matching variables and adjusted for exact age, marital status, education level, cigarette
smoking, height, and body mass index. The x2 test statistics were calculated by comparing the x2 values of models with and without the addition of a
study (or study type)-times-linear trend interaction term. The 10th and 90th percentiles of folate concentration for each study (indicating the
magnitude of an 80-percentile increase) are as follows: ATBC (5.4 and 13.2 nmol/l), CARET (6.5 and 42.2 nmol/l), EPIC phase 1 (4.5 and 26.9 nmol/l),
EPIC phase 2 (8.0 and 33.2 nmol/l), Janus (10 and 20 nmol/l), NSHDC (3.4 and 9.4 nmol/l), and ProtecT (7.9 and 44.7 nmol/l).
ATBC = Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study; CARET = Carotene and Retinol Efficacy Trial; CI = confidence interval;
EPIC = European Prospective Investigation into Cancer and Nutrition; NSHDC = Northern Sweden Health and Disease Study cohort; OR = odds ratio;
ProtecT = Prostate Testing for Cancer and Treatment Trial.
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[(Fig._3)TD$FIG]
Fig. 3 – Odds ratios and 95% confidence intervals for prostate cancer per 80-percentile increase in (a) in circulating folate and (b) in circulating vitamin
B12 by subgroups. The odds ratios are conditioned on the matching variables and adjusted for exact age, marital status, education level, cigarette
smoking, height, and body mass index. Tests for heterogeneity were calculated by entering a term for the interaction between an 80-percentile
increase in concentration and the subgroup variable into the conditional logistic regression models, and the statistical significance of the interaction
terms were calculated with likelihood ratio tests.
CI = confidence interval; OR = odds ratio.
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[(Fig._4)TD$FIG]
Fig. 4 – Odds ratios and 95% confidence intervals for (a) advanced stage, (b) aggressive, and (c) high-grade prostate cancer by study-specific fifths of
circulating folate concentration. The odds ratios are conditioned on the matching variables and adjusted for exact age, marital status, education level,
cigarette smoking, height, and body mass index. The odds ratio per 80%le increase in folate concentration and p value for trend were calculated by
replacing the fifths of the folate with a continuous variable that was scored 0, 0.25, 0.5, 0.75, and 1 in the conditional logistic regression model.
80%le = 80-percentile; CI = confidence interval; OR = odds ratio; Ptr = p value for trend.
E U RO P E AN URO LOGY 7 0 ( 2 0 1 6 ) 9 4 1 – 9 5 1948those on a normal or high folate diet [17]. Furthermore, in a
small sample of radical prostatectomy patients, increased
cancer cell proliferation was observed in prostate samples
from men with higher serum concentrations of folate
[18]. There is also some evidence from genetic studies of a
role for folate in the development of aggressive PCa, for
example, an association of the homozygote TT genotype of
the methylenetetrahydrofolate reductase gene (MTHFR
C677T) with lower circulating folate concentrations and
reduced risk for aggressive PCa [12,19].
There has been little research into whether folate intake
in menwith PCamight affect the progression of the disease,
but the data available have not shown any evidence of an
association of folate intake with PrCa progression [20] or
survival [21]. To understand better the potential role of
folate in PCa progression, more data are needed from large
observational studies (or randomised trials) with long-term
follow-up, circulating folate, and PCa tissue to investigate
whether higher circulating concentrations are associated
with quantifiable local molecular changes.The modest 12% increased risk of PCa associated with a
higher vitamin B12 concentration is similar to that reported
from a meta-analysis of five studies (fixed-effects pooled
estimate per 100-pmol/l increment, OR: 1.10 [95% CI, 1.03–
1.18]) [3], of which three studies were eligible for inclusion
in the present analysis and contributed 45% of the data. The
current analysis suggests that this modest association
might be modified by smoking, with higher vitamin B12
associated with an increased risk of PCa in never smokers
but not in current or past smokers. Circulating vitamin B12
did not differ by smoking status in our study, and it is
possible that our finding may be due to chance, given the
multiple statistical tests performed.
The strengths of the current analysis include the large
sample size and the detailed data on participant character-
istics. The prospective design, with blood collected several
years before diagnosis in most studies, allowed us to
evaluate the association by time from blood collection to
diagnosis, the results of which do not suggest that the
observed associations are due to reverse causation bias.
E U RO P E AN URO LOG Y 7 0 ( 2 0 1 6 ) 9 4 1 – 9 5 1 949Changing diagnostic practices over time and between
settings, including increasing use of PSA testing (used to
a greater extent in the United States [22] than in Europe
[23]), and updates to Gleason scoring will have influenced
rates of case ascertainment, lead time to diagnosis, and
disease classification during the follow-up period. Unfortu-
nately, individual participant screening histories and blood
PSA levels at recruitment were not available for four of the
six studies included in the analysis, so it was not possible to
take these factors into account. However, our stringent
definition for high-grade PCa (Gleason sum of 8 or
equivalent) means that the association seen for this
subgroup is unlikely to include low- or intermediate-grade
cancers.
The current analysis is based on measurements of folate
and B12 concentrations taken from a single blood sample
from each participant, which may not characterise usual or
longer term blood concentrations, leading to some attenu-
ation of risk estimates. Previous studies have reported that
the within-person reproducibility over a 1- to 4-yr period is
fair to good for folate (intraclass correlation coefficient:
0.47–0.61) and better for vitamin B12 (intraclass correlation
coefficient: 0.61–0.87) [24–26]. However, mandatory folic
acid fortification of cereals in the United States [27] during
the follow-up period of the CARET study and some
voluntary fortification of foods in Europe [28] might further
contribute to misclassification of usual exposure in the
absence of repeated measures.
Variation in circulating folate and vitamin B12 concen-
trations between the contributing studies is probably
mostly real (ie, due to differences in intake [29]), although
it is likely that there is also some artefactual variation due to
differences in blood processing, storage, and assay meth-
odology [30–34]. However, samples from all studies (with
the exception of a small subcohort of the EPIC study) were
processed within a short time of blood collection, and
samples from the Janus study (stored at 25 8C) were
analysed using a novel assay capable of recovering degraded
folate [35,36].
5. Conclusions
Higher folate concentration was associated with an
increased risk of high-grade disease that was not evident
for low-grade disease. This finding suggests a possible role
for folate in the progression of clinically relevant PCa and
warrants further investigation.
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